Co-diagnostics Newsroom

Co-Diagnostics Analyst Ratings

BenzingaAug 12 14:21 ET

Hold Rating Maintained for Co-Diagnostics Amidst Revenue Growth and Development Progress

TipRanksAug 12 09:57 ET

Co-Diagnostics Analyst Ratings

BenzingaJun 17 10:57 ET

Co-Diagnostics Analyst Ratings

BenzingaMay 13 07:07 ET

Co-Diagnostics Analyst Ratings

BenzingaMar 15 06:47 ET

Maintaining Hold on Co-Diagnostics Amid Revenue Decline and Potential EUA Boost

TipRanksMar 15 06:31 ET

Co-Diagnostics Analyst Ratings

BenzingaDec 29, 2023 06:32 ET

Analysts' Opinions Are Mixed on These Healthcare Stocks: Natera (NTRA) and Co-Diagnostics (CODX)

TipRanksDec 29, 2023 06:20 ET

Co-Diagnostics Analyst Ratings

BenzingaNov 13, 2023 10:33 ET

Hold Rating on Co-Diagnostics: Revenue Decline Offset by Grant, FDA Submission on the Horizon, and Strong Cash Position Amid Potential Risks

TipRanksNov 13, 2023 06:40 ET

HC Wainwright & Co. Maintains Neutral on Co-Diagnostics, Lowers Price Target to $2

BenzingaAug 14, 2023 06:46 ET

Co-Diagnostics Analyst Ratings

BenzingaAug 14, 2023 06:46 ET

HC Wainwright & Co. Reiterates Neutral on Co-Diagnostics, Maintains $3 Price Target

BenzingaMay 15, 2023 06:50 ET

Co-Diagnostics (CODX) Receives a Hold From H.C. Wainwright

TipRanksMay 15, 2023 06:25 ET

HC Wainwright & Co. Downgrades Co-Diagnostics to Neutral, Lowers Price Target to $3

BenzingaMar 20, 2023 07:51 ET

H.C. Wainwright Remains a Buy on Co-Diagnostics (CODX)

TipRanksFeb 23, 2023 07:32 ET

Co-Diagnostics Analyst Ratings

BenzingaFeb 23, 2023 06:18 ET

HC Wainwright & Co. Reiterates Buy on Co-Diagnostics, Maintains $6 Price Target

BenzingaFeb 23, 2023 06:14 ET

Co-Diagnostics Analyst Ratings

Benzinga Analyst RatingsNov 14, 2022 06:29 ET

HC Wainwright & Co. Maintains Buy on Co-Diagnostics, Lowers Price Target to $6

Benzinga Real-time NewsNov 14, 2022 06:28 ET